Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study
Aim: To characterize breakthrough cancer pain (BTcP) in patients with lung cancer. Methods: This was a secondary analysis of multicenter study of patients with BTcP. Background pain intensity and opioid dose were recorded. The number of BTcP episodes, their intensity, predictability, onset, duration...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/5/1337 |
| _version_ | 1797568834429779968 |
|---|---|
| author | Sebastiano Mercadante Francesco Masedu Marco Valenti Federica Aielli |
| author_facet | Sebastiano Mercadante Francesco Masedu Marco Valenti Federica Aielli |
| author_sort | Sebastiano Mercadante |
| collection | DOAJ |
| description | Aim: To characterize breakthrough cancer pain (BTcP) in patients with lung cancer. Methods: This was a secondary analysis of multicenter study of patients with BTcP. Background pain intensity and opioid dose were recorded. The number of BTcP episodes, their intensity, predictability, onset, duration and interference with daily activities were collected. Opioids used for BTcP, the mean time to meaningful pain relief after taking medication, satisfaction and adverse effects were assessed. Results: 1087 patients with lung cancer were examined. In comparison with other tumors, patients with lung cancer showed: higher background pain intensity (<i>p</i> = 0.006), lower opioid doses (<i>p</i> = 0.005), higher intensity of BTcP (<i>p</i> = 0.005), movement (79.5%) and cough (8.2%), as principal triggers for predictable BTcP (<i>p</i> < 0.009), larger BTcP interference with daily activity (<i>p</i> = 0.0001), higher use of adjuvants (<i>p</i> = 0.0001). No relevant differences in the other parameters examined were found. Conclusion: Patients with lung cancer have their own peculiarities, including higher basal and BTcP pain intensity and the use of more adjuvant drugs for background pain. The most frequent triggers for predictable BTcP are movement and cough. Future studies should be performed to analyze the prevalence of BTcP in patients with different lung cancers as well as the optimal management strategy for background pain and BTcP. |
| first_indexed | 2024-03-10T20:02:42Z |
| format | Article |
| id | doaj.art-bde853819878499b9187e681e9184b00 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T20:02:42Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-bde853819878499b9187e681e9184b002023-11-19T23:27:28ZengMDPI AGJournal of Clinical Medicine2077-03832020-05-0195133710.3390/jcm9051337Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS StudySebastiano Mercadante0Francesco Masedu1Marco Valenti2Federica Aielli3Main Regional Center for Pain, Pain Relief and Supportive/Palliative Care, La Maddalena Cancer Center, 90146 Palermo, ItalyDepartment of Biotechnological and Applied Clinical Sciences, Section of Clinical Epidemiology and Environmental Medicine, University of L’Aquila, 67100 L’Aquila, ItalyDepartment of Biotechnological and Applied Clinical Sciences, Section of Clinical Epidemiology and Environmental Medicine, University of L’Aquila, 67100 L’Aquila, ItalyDepartment of Medical Oncology, AUSL Teramo, 64100 Teramo, ItalyAim: To characterize breakthrough cancer pain (BTcP) in patients with lung cancer. Methods: This was a secondary analysis of multicenter study of patients with BTcP. Background pain intensity and opioid dose were recorded. The number of BTcP episodes, their intensity, predictability, onset, duration and interference with daily activities were collected. Opioids used for BTcP, the mean time to meaningful pain relief after taking medication, satisfaction and adverse effects were assessed. Results: 1087 patients with lung cancer were examined. In comparison with other tumors, patients with lung cancer showed: higher background pain intensity (<i>p</i> = 0.006), lower opioid doses (<i>p</i> = 0.005), higher intensity of BTcP (<i>p</i> = 0.005), movement (79.5%) and cough (8.2%), as principal triggers for predictable BTcP (<i>p</i> < 0.009), larger BTcP interference with daily activity (<i>p</i> = 0.0001), higher use of adjuvants (<i>p</i> = 0.0001). No relevant differences in the other parameters examined were found. Conclusion: Patients with lung cancer have their own peculiarities, including higher basal and BTcP pain intensity and the use of more adjuvant drugs for background pain. The most frequent triggers for predictable BTcP are movement and cough. Future studies should be performed to analyze the prevalence of BTcP in patients with different lung cancers as well as the optimal management strategy for background pain and BTcP.https://www.mdpi.com/2077-0383/9/5/1337lung cancercancer painbreakthrough cancer painopioids |
| spellingShingle | Sebastiano Mercadante Francesco Masedu Marco Valenti Federica Aielli Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study Journal of Clinical Medicine lung cancer cancer pain breakthrough cancer pain opioids |
| title | Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study |
| title_full | Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study |
| title_fullStr | Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study |
| title_full_unstemmed | Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study |
| title_short | Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study |
| title_sort | breakthrough pain in patients with lung cancer a secondary analysis of iops ms study |
| topic | lung cancer cancer pain breakthrough cancer pain opioids |
| url | https://www.mdpi.com/2077-0383/9/5/1337 |
| work_keys_str_mv | AT sebastianomercadante breakthroughpaininpatientswithlungcancerasecondaryanalysisofiopsmsstudy AT francescomasedu breakthroughpaininpatientswithlungcancerasecondaryanalysisofiopsmsstudy AT marcovalenti breakthroughpaininpatientswithlungcancerasecondaryanalysisofiopsmsstudy AT federicaaielli breakthroughpaininpatientswithlungcancerasecondaryanalysisofiopsmsstudy |